We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01686776
Recruitment Status : Unknown
Verified January 2013 by Ake Norberg, Karolinska Institutet.
Recruitment status was:  Recruiting
First Posted : September 18, 2012
Last Update Posted : January 17, 2013
Sponsor:
Information provided by (Responsible Party):
Ake Norberg, Karolinska Institutet

Brief Summary:

This is a prospective, validation study of a extempore made tracer compared with a commercial. Studies with tracer have no medical effects but are used for studying human physiology, in this case pharmacokinetic variables of endogenous albumin distribution and turnover at different levels of inflammation.

  1. Primary Objective:

    - Do the extempore made tracer 123-iodine labeled albumin an commercially manufactured SERALB-125 give identical values of calculated blood plasma volume and capillary leakage measured as transcapillary escape rate of albumin?

  2. Secondary Objective:

    • How do three different measures of albumin turnover correlate in volunteers?
    • How do the pharmacokinetic parameters of endogenous albumin vary between the three study groups?

Condition or disease Intervention/treatment Phase
Healthy SIRS Other: 123 I-HSA + 125 I HSA Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Prospective Validation Study in Healthy Volunteers, Patients With Acute Inflammation and Patients Scheduled for Major Abdominal Surgery
Study Start Date : September 2012
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Altretamine
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 123 I-HSA + 125 I-HSA
Healthy Volunteers, N=16
Other: 123 I-HSA + 125 I HSA
Compare and validate the method of measuring albumine turnover rate
Experimental: 123 I- HSA + 125 I-HSA
Patients, planned for elective Major Abdominal Surgery, N=16
Other: 123 I-HSA + 125 I HSA
Compare and validate the method of measuring albumine turnover rate
Experimental: 123-I-HSA+125 I-HSA
Patients, with a acute pancreatitis or cholecystitis, N=16
Other: 123 I-HSA + 125 I HSA
Compare and validate the method of measuring albumine turnover rate



Primary Outcome Measures :
  1. Transcapillary Escape Rate (TER)of Albumin [ Time Frame: 42 days ]
    Is the measured value for 123-I-HSA and 125I-HSA identical/equal regarded TER and plasma volume (PV)?


Secondary Outcome Measures :
  1. Fractional catabolic rate (FCR) [ Time Frame: 42 days ]
    Non compartmental analysis (NCA) and AUC (time-conc) will be determine the pharmacokinetics like clearance, distribution volume and absolute catabolic rate


Other Outcome Measures:
  1. plasma albumin turnover rate [ Time Frame: 42 days ]
    How well does the variables FSR, FCR1, FCR30 correlate? How does the pharmacokinetic parameters differ/varies between the three groups?



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers (treatment arm I)
  • on contraceptive agent and/or contraceptive device
  • visual peripheral veins
  • signed informed consent
  • planned for elective larger interabdominal surgery (treatment arm II)
  • patients with a acute pancreatitis or cholecystitis (treatment arm III)

Exclusion Criteria:

  • pregnant women and/or lactating
  • allergy towards excipients in 123 I HSA or 125 I HSA
  • participates in another study involving radiation or stabile isotopes within a period of 60 days to study start
  • it is the opinion of the principle investigator that the patient/subject should not participate for his/hers own good

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01686776


Contacts
Contact: Åke Norbebrg, M.D PhD +46-8-58585159 ake.norberg@karolinska.se

Locations
Sweden
Karolinska University Hospital, Huddinge Recruiting
Stockholm, Sweden, SE-141 86
Principal Investigator: Åke Norberg, M.D.,PhD.         
Sponsors and Collaborators
Ake Norberg
Investigators
Study Chair: Olav Rooyackers, PhDProfessor Karolinska University Hopsital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ake Norberg, M.D, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT01686776     History of Changes
Other Study ID Numbers: 3.00 # amended version 1.1
First Posted: September 18, 2012    Key Record Dates
Last Update Posted: January 17, 2013
Last Verified: January 2013

Keywords provided by Ake Norberg, Karolinska Institutet:
Plasma albumine
Plasma volume
Transcapillary escape rate
Inflammation
Circulation